I
ron homeostasis in patients with heart failure (HF) is abnormal because of the effects of proinflammatory cytokines on the key liver-derived iron regulatory protein hepcidin. 1, 2 Increased hepcidin synthesis in response to proinflammatory signals induces a state of functional iron deficiency characterized by decreased dietary iron absorption, reduced bioavailability of stored iron for erythropoiesis in the bone marrow, and increased iron stores in the liver and other nonerythrocyte cell types. 1 Functional iron deficiency is present in 50% of subjects with HF and is associated with exercise intolerance and greater mortality risk in patients with (hazard ratio (HR), 1.71; 95% confidence interval (CI), 1.24-2.36; P=0.001) or without (HR, 1.44; 95% CI, 1.11-1.87; P=0.006) concomitant anemia. 3, 4 Two previous multisite randomized double-blind placebo-controlled clinical trials have demonstrated that repletion of iron stores with intravenous ferric carboxymaltose is associated with improvement in measures of submaximal exercise capacity and functional capacity in subjects with HF with reduced ejection fraction (HFrEF) and biochemical markers consistent with functional iron deficiency. 5 In this issue of Circulation, van Veldhuisen and colleagues 6 report the findings of a well-designed and -executed prospective multisite open-label randomized clinical trial with blinded end point assessment to determine the effects of intravenous iron repletion with ferric carboxymaltose versus usual care (including optional oral iron supplementation) on peak aerobic capacity in symptomatic patients with HFrEF and biochemical markers consistent with functional iron deficiency.
A strict interpretation of the findings based on the prespecified intent-to-treat analysis demonstrates a significant difference in the change in peak oxygen uptake (determined during symptom-limited graded bicycle ergometer exercise) in subjects assigned to active treatment with ferric carboxymaltose when compared with that in subjects treated with usual care over 24 weeks. This finding is based on the imputation of missing values as last value carried forward or an assigned value of 0 for subjects who died during the study. Although this imputation approach is commonly recommended for the handling of missing data in clinical trials, 7 the authors correctly point out that the findings of the prespecified primary analysis should be considered equivocal because of inconsistent findings based on other imputation methods, which failed to demonstrate significant differences in peak oxygen uptake between the groups. Physiological considerations also challenge the internal validity of the reported peak oxygen uptake data and interpretation of the study findings. Maximal skeletal muscle oxygen extraction at peak exercise is augmented in patients with HF when compared with controls without HF in proportion to the severity of aerobic impairment. 8 According to the principles of the Fick equation, the significant increase in hemoglobin level in the ferric carboxymaltose group (≈1 g/dL increase from baseline) would be expected to be associated with an increase in the maximal arteriovenous difference in oxygen content and a concomitant increase in peak oxygen uptake. However, in all of the presented analyses, peak oxygen uptake did not increase in the ferric carboxymaltose group, and no correlation occurred between change in hemoglobin and change in peak oxygen uptake in response to therapy. The absence of change suggests that iron therapy might have other physiological effects that diminish oxygen utilization at peak exercise, or that other unmeasured factors, possibly related to the openlabel design, may have impacted exercise performance and measured peak oxygen uptake after treatment.
In contrast to the uncertainty related to the interpretation for the primary end point of peak oxygen uptake, measures of functional capacity based on subjective assessment by investigators and subjects were significantly improved in the ferric carboxymaltose group at 24 weeks compared with those in the usual care group, with consistent findings for different imputation techniques. This finding is consistent with previous randomized trials of intravenous iron repletion in patients with HFrEF 5 and, taken together with the absence of a significant association between change in hemoglobin level and change in peak oxygen uptake, suggests that iron homeostasis may be impacting submaximal exercise performance by mechanisms independent of increased hemoglobin-mediated oxygen delivery.
The apparent dissociation between the effects of intravenous iron on submaximal versus maximal exercise performance in HF may be mechanistically linked to the effects of iron deficiency on skeletal muscle mitochondrial function. Iron is an essential cofactor in the cytochromes and iron-sulfur proteins in the mitochondrial electron transport chain. 9 Experimental iron deficiency in rats is associated with decreased skeletal muscle mitochondrial oxidative enzyme activity, decreased mitochondrial volume, increased lactate production during exercise, and decreased rate of phosphocreatine resynthesis after exercise. 10, 11 These mitochondrial changes induced by iron depletion are associated with a reduction in endurance capacity and are reversible with iron repletion. Mitochondrial dysfunction because of reduced skeletal muscle iron stores may impair work efficiency and submaximal exercise performance in patients with HF. Endurance performance at submaximal exercise levels is determined by the efficiency of mitochondrial conversion of oxygen to adenosine triphosphate (mitochondrial coupling efficiency [ε M ]) and efficiency of the conversion of adenosine triphosphate to physical work (contractile coupling efficiency [ε C ]). Work efficiency during submaximal steady-state exercise is decreased in subjects with HF when compared with controls without HF and is associated with greater symptoms as assessed by a disease-specific quality of life questionnaire. 12 Additional research is needed to determine the effects of iron repletion on skeletal muscle metabolism and work efficiency in patients with HFrEF with iron deficiency.
In conclusion, available evidence suggests that iron deficiency in HF is mechanistically linked to impaired functional capacity independent of the hemoglobin level. Oral iron replacement therapy was associated with minimal changes in biomarkers of iron stores and did not improve submaximal or maximal exercise in patients with HF when compared with placebo. 13 The current study by van Veldhuisen and colleagues 6 adds to the existing body of literature demonstrating that intravenous iron administered over 6 to 12 months can safely improve functional capacity in patients with HFrEF and iron deficiency. Based on these cumulative data, the 2017 update of the American Heart Association/American College of Cardiology guideline for the management of HF recommends surveillance laboratory monitoring for anemia and iron stores and has added a IIB recommendation for the use of intravenous iron to improve functional status in patients with evidence of iron deficiency.
14 The optimal dosing strategy and formulation of intravenous iron for use in HF has not been determined, but total doses ranging from 1000 to 1500 mg have been commonly used in existing HFrEF studies. 5 Although no observed signal of harm is associated with intravenous iron in patients with HFrEF, all intravenous iron preparations have a low risk of hypersensitivity reactions, including rare cases of anaphylaxis, 5 and the long-term safety of intravenous iron therapy in HF has not yet been determined. Prospective randomized controlled trials of the effects of intravenous iron therapy on clinical outcomes in HF are currently enrolling subjects (URL: www.clinicaltrials.gov. Unique identifiers: NCT0303793, NCT02642562, NCT03036462). Pending completion of these outcomes trials, it may be prudent to limit intravenous iron use to 6 months of therapy in symptomatic subjects with HFrEF with evidence of iron deficiency and concomitant anemia. 
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